|
Age, y, mean ± SD
|
29.1 ± 9.1
|
|
Male, n (%)
|
11 (57.9)
|
|
Montreal classification, n (%)
|
|
Age at diagnosis
|
|
< 16
|
0 (0)
|
|
16–40
|
17 (89.5)
|
|
> 40
|
2 (10.5)
|
|
Behavior
|
|
B1
|
1052.6)
|
|
B2
|
5 (26.3)
|
|
B3
|
4 (21.1)
|
|
Location
|
|
L1
|
2 (10.5)
|
|
L2
|
1 (5.3)
|
|
L3
|
16 (84.2)
|
|
L4
|
0 (0)
|
|
Disease duration, y, mean ± SD
|
5.5 ± 4.7
|
|
BMI at diagnosis, mean ± SD
|
19.5 ± 2.4
|
|
EIM, n (%)
|
1 (5.3)
|
|
Perianal disease, n (%)
|
10 (52.6)
|
|
Previous biologics exposure, n (%)
|
17 (89.5)
|
|
1
|
15 (78.9)
|
|
2
|
1 (5.3)
|
|
3
|
0 (0)
|
|
4
|
1 (5.3)
|
|
Intestinal surgeries, n (%)
|
8 (42.1)
|
|
Concomitant drugs, n (%)
|
|
Corticosteroid
|
1 (5.3)
|
|
Thiopurine
|
1 (5.3)
|
|
UST administration interval, n (%)
|
|
Q12w
|
14 (73.7)
|
|
Q8w
|
5 (26.3)
|
